1. asheymommy
2. marz11
3. dynamichealthsol
4. franciscaguila78
5. badaleyes
1.dynamichealthsol 02/02/2018
Beats EPS estimates by $0.04.
2.asheymommy 03/01/2018
3.marz11 04/10/2018
Merck monotherapy met primary endpoint in phase 3 keynote-042 study, significantly improving OS as first-line…
4.badaleyes 02/02/2018
Big news - Sees FY18 revs $41.2-42.7 bln vs $41.10 bln
5.dynamichealthsol 01/03/2018
er details
6.dynamichealthsol 02/21/2018
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck's Leading Immuno-Oncology Pipeline
7.dynamichealthsol 04/16/2018
Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamou
8.asheymommy 02/13/2018
Company will be stopping protocol 019, also known as the APECS study, a Phase 3 study
9.asheymommy 01/26/2018
today > $MRK - CHMP gave positive opinions for three medicines to treat type 2 diabetes: Segluromet (ertugliflozin / metform…
10.franciscaguila78 03/15/2018
Cautious commentary on Mad Money show
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW